Date: 2014-01-03
Type of information: R&D agreement
Compound: cyclin-dependent kinase 9 (CDK9) inhibitor program
Company: Probiodrug (Germany) AstraZeneca (UK)
Therapeutic area: Cardiovascular diseases - Inflammatory diseases
Type agreement: sale
Action mechanism:
Disease:
Details: * On January 3, 2014, Probiodrug has announced the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.
Financial terms: Financial terms of the asset purchase were not disclosed. Probiodrug was advised by UP Biotech Management AG in this transaction.
Latest news:
